Screening for type 2 diabetes

Diabetes Care

Volumn 23, Issue 10, 2000, Pages 1563-1580

  Engelgau, Michael M ^a   Venkat Narayan, K M ^a   Herman, William H ^b  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY DIAGNOSIS; HEALTH CARE COST; HUMAN; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PUBLIC HEALTH; REVIEW; SYMPTOMATOLOGY;

EID: 0033807708     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.10.1563     Document Type: Review

References (216)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994
2. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections
3. Undiagnosed NIDDM: Clinical and public health issues
4. Health care expenses for people with diabetes mellitus, 1992
5. Economic consequences of diabetes mellitus in the U.S. in 1997
6. How should we respond to the worldwide diabetes epidemic?
7. Screening for NIDDM: Opportunities for detection, treatment, and prevention
8. Screening for NIDDM: Why is there no national program?
9. Screening for NIDDM in nonpregnant adults: A review of principles, screening tests, and recommendations
10. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: Provisional report of a WHO consultation
11. Population screening for diabetes mellitus
12. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
13. The prevalence of diabetes in Rio de Janeiro, Brazil: The Cooperative Group for the Study of Diabetes Prevalence in Rio De Janeiro
14. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the U.S. population aged 70-74
15. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults
16. Non-insulin-dependent diabetes mellitus in black and white Americans
17. Diabetes in Africa
18. Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Nutritional Examination Survey, 1982-1984
19. Changing prevalence of retinopathy in newly diagnosed non-insulin-dependent diabetes mellitus patients in Hong Kong
20. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican-Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study
21. Prevalence of retinopathy in people with diabetes, impaired glucose tolerance, and normal glucose tolerance
22. United Kingdom Prospective Diabetes Study: Diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors
23. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis
24. Epidemiology of persistent proteinuria in type II diabetes mellitus: Population-based study in Rochester, Minnesota
25. Impaired glucose tolerance in the U.S. population
26. Deciding about screening
27. Developing screening in the NHS
28. Prevention: How much harm? How much benefit? I. Influence of reporting methods on perception of benefits
29. The scope of screening
30. Prevention: How much harm? How much benefit? IV. The ethics of informed consent for preventive screening programs
31. Prevention: How much harm? How much benefit? III. Physical, psychological and social harm
32. Prevention: How much harm? how much benefit? II. Ten potential pitfalls in determining the clinical significance of benefits
33. Screening for non-insulin-dependent diabetes mellitus in the elderly
34. Screening for diabetes
35. Screening for non-insulin-dependent diabetes mellitus: Where to draw the line?
36. Assessing the effectiveness of community screening programs
37. Vision disorders in diabetes
38. Diabetic retinopathy
39. Visual impairment in diabetes
40. Effect of transplantation on Medicare end-stage renal disease program
41. The incidence of end-stage renal disease in type I and type II diabetes mellitus
42. The epidemiology of lower-extremity amputation in diabetic individuals
43. The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community
44. The prevalence and incidence of lower-extremity amputation in a diabetic population
45. Trends in diabetes and diabetic complications
46. Closing the gap: The problem of diabetes mellitus in the United States
47. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus
48. Mortality among diabetics in a national sample
49. The Economics of Diabetes and Diabetes Care. A Report of the Diabetes Health Economics Study Group. International Diabetes Federation
50. Epidemiology of diabetes mellitus in the elderly in northern Greece: A population study
51. Case control studies for estimation of the natural history of preclinical disease from screening data
52. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus
53. Prevalence of microalbuminuria in older-onset diabetes
54. Neuropathy in diabetes
55. Heart disease in diabetes
56. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk
57. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults
58. The diagnosis and classification of diabetes mellitus in nonpregnant adults
59. Validity of case-control studies and randomized controlled trials of screening
60. The Cochrane Collaborative Diabetes Review Group
61. Cochrane Collaboration Review Group: Diabetes
62. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
63. Intensive insulin therapy present in the original progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
64. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
65. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
66. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37)
67. Estimating benefits of glycemic control in microvascular complication in type 2 diabetes
68. The cost-effectiveness of screening for type 2 diabetes
69. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
70. Effects of intensive blood-pressure lowering and low-dose aspirin on patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
71. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI)
72. Management of dyslipidemia in adults with diabetes (Position Statement)
73. How effective are treatments for diabetic retinopathy?
74. Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of diabetic retinopathy study (DRS) findings. DRS Rep. No. 8
75. Photocoagulation for diabetic macular edema
76. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
77. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
78. Risk factors for amputation in patients with diabetes mellitus: A case-control study
79. Lower-extremity amputation in people with diabetes: Epidemiology and prevention
80. An evaluation of methods for estimating the area under the receiver operating characteristic (ROC) curve
81. The meaning and use of the area under a receiver operating characteristic (ROC) curve
82. A method of comparing the areas under receiver operating characteristic curves derived from the same cases
83. The area above the ordinal dominancy graph and the area below the receiver operating characteristic graph
84. The use of relative operating characteristic (ROC) curves in test performance evaluation
85. A VisiCalc program for estimating the area under a receiver operating characteristic (ROC) curve
86. American diabetes alert
87. Community screening for diabetes: Low detection rate in a low-risk population
88. The American Diabetes Association screening questionnaire for diabetes: Is it worthwhile in the U.K.?
89. Take the test: Know the score: A new questionnaire to identify persons at increased risk for undiagnosed diabetes mellitus
90. Response to Knudson et al
91. Screening for type 2 diabetes (Position Statement)
92. Utility of the American Diabetes Association risk test in a community screening program
93. Performance of an NIDDM screening questionnaire based on symptoms and risk factors
94. The American Diabetes Association risk test for diabetes: Is it a useful screening tool?
95. Sensitivity and specificity of five screening tests for diabetes in ten countries
96. A model of early diagnosis in type 2 diabetes mellitus in primary health care
97. Comparison of screening tests for non-insulin-dependent diabetes mellitus
98. The glycohaemoglobin assay as a screening test for diabetes mellitus: The Islington Diabetes Survey
99. Self testing for diabetes mellitus
100. Epidemiologic studies of diabetes mellitus in Saudi Arabia. I. Screening of 3,158 males in King Saud University
101. Diabetes detection with a comparison of screening methods
102. Community screening for non-insulin-dependent diabetes mellitus: Self-testing for post-prandial glycosuria
103. Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening?
104. Comparison of glycosylated hemoglobin and fasting plasma glucose with two-hour post-load plasma glucose in the detection of diabetes mellitus
105. Fasting plasma glucose in screening for NIDDM in the U.S. and Israel
106. Evaluation of three potential screening tests for diabetes in a biethenic population
107. The abbreviated glucose tolerance test in screening for diabetes: The Islington Diabetes Study
108. Receiver operating characteristic analysis on fasting plasma glucose, HbA(1c), and fructosamine on diabetes screening
109. Evaluation of fasting plasma glucose as a screening test for NIDDM in older adults: Rancho Bernardo Study
110. Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose tolerance
111. Screening for diabetes: Does measurement of serum fructosamine help?
112. Screening for non-insulin-dependent diabetes mellitus and impaired glucose tolerance in a Dunedin general practice: Is it worth it?
113. A random blood sugar diabetes detection survey
114. Community screening for glucose intolerance in middle-aged Icelandic men
115. Effectiveness of mass screening for diabetes mellitus using random capillary blood glucose measurements
116. Evaluation of fasting plasma glucose as a screening test for diabetes mellitus in Singaporean adults
117. Fasting plasma glucose in screening for diabetes in the Taiwanese population
118. Evaluation of the new fasting plasma glucose cutpoint of 7.0 mmol/l in detection of diabetes mellitus in the Thai population
119. Fasting plasma glucose as a screening test for diabetes mellitus
120. Combined use of a fasting plasma glucose concentration and HbA(1c) or fructosamine predicts the likelihood of having diabetes in high-risk subjects
121. The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT
122. Glycosylated hemoglobin determination from capillary blood samples: Utility in an epidemiologic survey of diabetes
123. Screening for diabetes mellitus in general practice using a reflectance meter system: The Islington Diabetes Survey
124. Supplement to the use of a paired value of fasting plasma glucose and glycated hemoglobin in predicting the likelihood of having diabetes
125. Hemoglobin A(1c) levels in a diabetes detection program
126. Is examination of fructosamine levels valuable as a diagnostic test for diabetes mellitus?
127. Relationship of glycosylated hemoglobin to oral glucose tolerance: Implications in diabetes screening
128. Glycosylated hemoglobin: A screening test for diabetes mellitus?
129. The values of glycosylated haemoglobin as a substitute for the oral glucose tolerance test in the detection of impaired glucose tolerance (IGT)
130. The relationship between glycosylated haemoglobin levels and various degrees of glucose intolerance
131. 1 and fructosamine in diagnosis of glucose tolerance abnormalities
132. Glycosylated hemoglobin in the diagnosis of non-insulin-dependent diabetes mellitus
133. Glycated hemoglobin: Is it a useful screening test for diabetes mellitus?
134. Glycosylated haemoglobin as an alternative to the glucose tolerance test for the diagnosis of diabetes mellitus
135. Glycosylated hemoglobin in the diagnosis of non-insulin-dependent diabetes mellitus
136. 1 and fructosamine in predicting impaired glucose tolerance: An alternative to OGTT to detect diabetes mellitus or gestational diabetes
137. Fructosamine in diabetes screening of the elderly
138. 1,5-Anhydroglucitol: A novel serum marker for screening and monitoring diabetes mellitus?
139. Fully antomated flow-injection system for quantifying 1,5-anhydro-D-glucitol in serum
140. Fully enzymatic method for determining 1,5-anhydro-D-glucitol in serum
141. Screening for diabetes mellitus in adults: The utility of random capillary blood glucose measurements
142. Recent progress in glycohemoglobin (HbA(1c)) testing
143. Biological variation of glycated hemoglobin: Implications for diabetes screening and monitoring
144. Unexplained variability of glycated hemoglobin in nondiabetic subjects not related to glycemia
145. 1 levels in normal glucose tolerance
146. Screening for non-insulin-dependent diabetes mellitus (NIDDM): How often should it be performed?
147. Frequency and determinants of screening for diabetes in the U.S.
148. Screening for diabetes: An alternative view
149. Point-of-care testing
150. 'Opportunistic' screening
151. Periodic health evaluation of adults: A survey of family physicians
152. Clinical health promotion and family physicians: A Canadian perspective
153. Opportunistic preventive services delivery: Are time limitations and patient satisfaction barriers?
154. Primary care physicians' use of office resources in the provision of preventive care
155. U.S. Preventive Services Task Force: Highlights of the 1996 report
156. Diagnosing the undiagnosed with diabetes
157. Outcomes of an insurance company-sponsored multichannel chemistry screening initiative
158. The 28th Amendment
159. Screening the population for diabetes
160. Economic analysis of diabetes interventions: Rationale, principles, findings, and interpretation
161. The cost-effectiveness of intensive therapy for diabetes mellitus
162. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
163. Cost effectiveness of LDL-C reduction in diabetic CHD patients: Implications from the Scandinavian Simvastatin Survival Study
164. Cost-effectiveness of detecting and treating diabetic retinopathy
165. An economic analysis of captopril in the treatment of diabetic nephropathy
166. Screening for mild thyroid failure at the periodic health examination: A decision and cost-effectiveness analysis
167. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics
168. Evaluating the cost-effectiveness of clinical and public health measures
169. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
170. Using economics to assess the place of screening
171. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
172. Screening for non-insulin-dependent diabetes mellitus (NIDDM): How often should it be done?
173. Effect of advertising on awareness of symptoms of diabetes among the general public: The British Diabetic Association Study
174. Screening for diabetes mellitus
175. Screening for non-insulin-dependent diabetes mellitus and impaired glucose tolerance in a Dunedin general practice: Is it worth it?
176. Diabetes screening in an outpatient oral surgery clinic
177. A community pharmacist-sponsored diabetes detection program
178. Diabetic screening program held in El Paso Nov 19-21, 1970
179. Diabetes screening for over 70 motor drivers
180. A project to reduce the burden of diabetes in the African-American community: Project DIRECT
181. Should medical screening of the elderly population be promoted?
182. Observations on the value of mass indiscriminate screening for diabetes mellitus based on a five-year follow-up
183. Some thoughts on early detection and intervention in diabetes mellitus
184. Community screening programs for diabetes?
185. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
186. Preventive care guidelines: 1991
187. The periodic health examination
188. The U.S. Preventive Services Task Force Guide to Clinical Preventive Services, Second Edition: AMA Council on Scientific Affairs
189. Diabetes screening practice among individuals age 45 years and older
190. Design and methods for a clinical trial in the prevention of type 2 diabetes
191. Screening for curly two disease: A transatlantic perspective
192. Diabetes in a managed care system
193. Assessing value for money in medical screening
194. A computerized health screening and follow-up system in diabetes mellitus
195. A random blood sugar diabetes detection survey
196. Analysis of tests for diabetes in 250,000 persons screened for diabetes using finger blood after a carbohydrate load
197. Diabetes detection with a comparison of screening methods
198. Effectiveness of mass screening for diabetes mellitus using random capillary blood glucose measurements
199. The American Diabetes Association risk test for diabetes
200. A method for the epidemiologic study of early diabetes